596 Potential public health impact of 13-valent pneumococcal conjugate vaccine use among US adults 65 years of age or older

Eitemau Tebyg

• Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States
  gan: Stoecker, Charles, et al.
  Cyhoeddwyd: (2016)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  gan: Tomczyk, Sara, et al.
  Cyhoeddwyd: (2014)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
  gan: Matanock, Almea, et al.
  Cyhoeddwyd: (2019)
• Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions
  gan: Kobayashi, Miwako, et al.
  Cyhoeddwyd: (2021)
• Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
  gan: Pilishvili, Tamara, et al.
  Cyhoeddwyd: (2017)